Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

SEBASTIAN EMILIO VENTURA SOTOEMILIA Mª ALORS PÉREZRAUL MIGUEL LUQUE HUERTASJUAN MANUEL JIMÉNEZ VACASMANUEL DAVID GAHETE ORTIZALEJANDRO IBÁÑEZ COSTAJUSTO PASTOR CASTAÑO FUENTES2026-01-292026-01-29202110.1186/s13046-021-02153-92-s2.0-85120754284https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/34312Cancer ResearchOncologyDysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugresearch article